)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Alterity Therapeutics
Alterity Therapeutics (ATH) investor relations material
Alterity Therapeutics Q1 2027 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2027 TU earnings summary29 Oct, 2026
Executive summary
FDA End-of-Phase 2 minutes aligned on ATH434’s Phase 3 design and registrational pathway in MSA; Phase 3 start-up activities are underway.
New U.S. composition-of-matter patent extends ATH434 protection to 2045 and supports potential development in Parkinson’s disease.
Financial highlights
Cash and cash equivalents were A$41.308 million at 30 September 2026, versus A$37.318 million at quarter start; quarterly operating cash outflow was A$1.339 million.
Operating cash flow included A$3.940 million in government grants and tax incentives; the reported FY2025 R&D refund totaled A$3,982,992, including interest.
Quarterly equity issuance proceeds were A$5.803 million, with A$0.305 million of transaction costs; net financing cash flow was A$5.469 million.
Outlook and guidance
Planned Phase 3 trial: approximately 200 patients randomized 1:1 to ATH434 50 mg or placebo twice daily for 12 months.
FDA agreed that one pivotal trial plus confirmatory evidence could support an NDA; Phase 2 ATH434-201 data are anticipated to provide the confirmatory evidence.
Phase 3 operational work includes protocol finalization, vendor selection, site qualification and manufacture of the first registration batch.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Alterity Therapeutics
- ATH434's phase III trial in MSA is set to begin, aiming for robust clinical and commercial impact.ATH
12th Annual Cantor Fitzgerald Global Healthcare Conference - Net loss increased 93% to A$23.4M as R&D and admin costs rose, but Phase 3 ATH434 trial is on track.ATHH2 2026
- ATH434 showed robust phase II efficacy in MSA, with phase III and major commercial potential ahead.ATHCanaccord Genuity's 46th Annual Growth Conference
- Regulatory pathway secured for ATH434 in MSA; Phase 3 trial and strong cash position support growth.ATHQ4 2026 TU
- ATH434 demonstrated significant efficacy and safety in MSA, advancing to Phase 3 trials.ATHCorporate presentation
- ATH434 advances toward Phase 3 with strong cash reserves and positive clinical data.ATHQ3 2026 TU
- ATH434 slowed MSA progression by up to 48% in phase II, supporting a pivotal phase III trial in 2026.ATHKOL event
- Net loss widened to A$19.1M as R&D spending rose; cash reserves at A$12.6M, equity raise planned.ATHH2 2024
- ATH434 showed strong Phase 2 efficacy in MSA, narrowing losses and boosting cash reserves.ATHH2 2025
Next Alterity Therapeutics earnings date
AGM 202620 Nov, 2026
Alterity Therapeutics
Next Alterity Therapeutics earnings date
AGM 202620 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Alterity Therapeutics Limited is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company specializes in small molecule treatments designed to target underlying biological processes associated with disorders such as Parkinsons and other neurological conditions. The company is headquartered in Melbourne, Australia, and its shares are listed on the ASX.